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Background: Heightened inflammation, including expression of COX-2, is associated with COPD pathogenesis. RelB
is an NF-κB family member that attenuates COX-2 in response to cigarette smoke by a mechanism that may involve
the miRNA miR-146a. There is no information on the expression of RelB in COPD or if RelB prevents COX-2 expression
through miR-146a.
Methods: RelB, Cox-2 and miR-146a levels were evaluated in lung fibroblasts and blood samples derived from
non-smokers (Normal) and smokers (At Risk) with and without COPD by qRT-PCR. RelB and COX-2 protein levels
were evaluated by western blot. Human lung fibroblasts from Normal subjects and smokers with and without
COPD, along with RelB knock-down (siRNA) in Normal cells, were exposed to cigarette smoke extract (CSE)
in vitro and COX-2 mRNA/protein and miR-146a levels assessed.
Results: Basal expression of RelB mRNA and protein were significantly lower in lung cells derived from smokers
with and without COPD, the latter of which expressed more Cox-2 mRNA and protein in response to CSE.
Knock-down of RelB in Normal fibroblasts increased Cox-2 mRNA and protein induction by CSE. Basal miR-146a
levels were not different between the three groups, and only Normal fibroblasts increased miR-146a expression
in response to smoke. There was a positive correlation between systemic RelB and Cox-2 mRNA levels and circulating
miR-146a levels were higher only in GOLD stage I subjects.
Conclusions: Our data indicate that RelB attenuates COX-2 expression in lung structural cells, such that loss of pulmonary
RelB may be an important determinant in the aberrant, heightened inflammation associated with COPD pathogenesis.
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Chronic obstructive pulmonary disease (COPD) is a het-
erogeneous disease associated with an enhanced, chronic
inflammatory response due to exposure to noxious parti-
cles or gases. Cigarette smoke is the single greatest risk
factor for developing COPD, with an estimated 80-90% of
COPD cases being due to chronic smoke exposure [1,2].* Correspondence: carolyn.baglole@mcgill.ca
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unless otherwise stated.Cigarette smoke contributes to COPD by inciting inflam-
mation, recruiting T cells, macrophages and neutrophils to
the lung in part via the induction of inflammatory media-
tors, including cyclooxygenase-2 (COX-2) [3-5]. COX-2
catalyzes the transformation of arachidonic acid (AA) into
thromboxanes and prostaglandins (PG) such as PGE2, an
immunoregulatory PG that is elevated in COPD subjects
[5,6]. Inhibition of COX-2-derived PGE2 also protects
against the development of emphysema [7], supporting a
role for COX-2 in the pathobiology of COPD. Numerous
cell types within the lung are capable of producing COX-2
in response to smoke, including lymphocytes, epithelialal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the primary role of the fibroblast is to synthesize and
maintain extracellular matrix (ECM), thereby providing
structure and support to the lung, there is now ample evi-
dence that fibroblasts contribute to chronic inflammation
by producing an array of cytokines, chemokines, lipid me-
diators and proteases [10-12]. Fibroblasts are among the
first cells in the lung which encounter cigarette smoke, po-
tently activating them to increase the production of IL-8,
COX-2 and other mediators involved in leukocyte recruit-
ment [4,13,14]. Alveolar fibroblasts also provide connec-
tion between type II pneumocytes and endothelial cells,
thereby providing migratory leukocytes with a directional
conduit [15]. Thus, disordered fibroblast behaviour may
regulate the switch to chronic, persistent inflammation in
part by their ability to promote the recruitment, survival
and retention of leukocytes and other immune cells to tar-
get organs such as the lung due to chronic smoke expos-
ure [10,16,17].
Lung fibroblasts derived from patients with COPD have
high intercellular adhesion molecule-1 (ICAM-1) expres-
sion and secrete more IL-6, IL-8, MMP-9 and PGE2
[2,16,18], the latter being due to increased COX-2 protein
expression [19]. The induction of COX-2 by cigarette
smoke is regulated at least partially by the transcription fac-
tor nuclear factor-κB (NF-κB) [4]. Activation of the canon-
ical NF-κβ pathway- typically composed of RelA and p50
subunits- increases gene transcription and the expression
of inflammatory proteins including IL-6, IL-8 and COX-2.
However, activation of this NF-κB pathway also increases
RelB expression [20], the key protein in the alternative
NF-κB pathway. RelB is sequestered in the cytosol by the
inhibitory NF-κB protein p100. Signal-specific processing of
p100 by the NF-κB-inducing kinase (NIK) produces p52,
which together with RelB translocate to the nucleus to
regulate gene expression [21]. Regulation of the alternative
NF-κB pathway during inflammatory conditions (TNF-α,
LPS, cigarette smoke, etc.) can occur via stabilization of
NIK, which increases NIK expression to allow efficient pro-
cessing of p100 to p52 [22]. Inflammatory stimuli can also
lead to the upregulation of RelB expression, enhanced nu-
clear localization [20,23,24] or processing/cleavage of RelB
protein [25,26]. Many of these may contribute to the ability
of RelB to modulate chronic inflammation. In this regard,
RelB prevents persistent non-infectious inflammation in
the liver and lung, a phenomena attributed to the suppres-
sive abilities of RelB in non-lymphoid tissue, possibly fibro-
blasts [27,28]. We have shown that RelB dampens cigarette
smoke-induced pulmonary inflammation both in vitro and
in vivo, including the expression of COX-2 [29,30]. COX-2
is over-expressed by COPD lung fibroblasts [19] and we
have shown that RelB protein is degraded by cigarette
smoke [29], rendering it possible that heightened smoke-
induced COX-2 expression in COPD is associated withabsent/low RelB expression. Moreover, whether systemic
RelB expression is also altered as a consequence of chronic
smoke exposure or COPD severity (i.e. GOLD stage) or is
associated with the expression of Cox-2 is also not known.
We recently published that in murine lung fibroblasts,
RelB suppression of cigarette smoke-induced COX-2 ex-
pression is due to up-regulation of the microRNA-146a
(miR-146a) [31]. miRNAs are single-stranded, non-coding,
22 nucleotide-long RNA which act posttranscriptionally to
inhibit protein expression [32] and are of increasing inter-
est as biomarkers for COPD [33]. Cigarette smoke alters
lung structural cell and circulating miRNA levels, includ-
ing miR-146a [31,34,35], an anti-inflammatory miRNA
that under-expressed in cytokine-stimulated lung fibro-
blasts derived from COPD patients, which ultimately re-
sults in higher COX-2 expression [36]. We postulate that
altered RelB expression in COPD-derived lung fibroblasts
facilitates cigarette smoke-induced COX-2 due to dysregu-
lation of miR-146a expression. Given that there is high
correlation of expression between immune cells and circu-
lating miRNA expression levels [37] and systemic expres-
sion miR-146a are now indicted in several diseases
including rheumatoid arthritis [37], we also postulated
that miR-146a levels would be associated with clinical fea-
tures of COPD in relation to changes in circulating RelB
expression.
Therefore, we first sought to investigate whether down-
regulation of RelB expression by cigarette smoke renders
lung cells unable to increase miR-146a levels, thereby po-
tentiating the induction of COX-2. Herein we show for the
first time that fibroblasts derived from smokers with and
without COPD have significantly lower RelB mRNA and
protein expression compared to Normal (non-smoker) fi-
broblasts. RelB expression decreases in Normal fibroblasts
exposed to cigarette smoke in vitro, and siRNA knock-
down of RelB potentiates Cox-2 mRNA and protein induc-
tion by cigarette smoke in Normal fibroblasts. Utilizing
blood samples from subjects participating in the Canadian
Chronic Obstructive Lung Disease (CanCOLD) platform
[38], we found that there was a significant positive correl-
ation between systemic RelB and Cox-2 mRNA expression.
Collectively, our results highlight the differential regulation
of RelB expression between lung structural cells and per-
ipheral blood and suggest that dysregulation of RelB levels
within pulmonary structural cells may be a contributing
factor in the heightened inflammatory response that is
characteristic of individuals who smoke.Materials and methods
Materials
All chemicals were purchased from Sigma (St. Louis,
MO) except MG-132 which was from Tocris Bioscience
(Minneapolis, MN).
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Lung tissue was obtained from individuals undergoing lung
resection surgery at McMaster University. Recruited indi-
viduals included those with COPD, subjects without COPD
but who were current or former smokers (At Risk) or non-
smokers without COPD (Normal). The clinical features of
the subjects from which the lung fibroblasts were derived
are given in Table 1. This study was approved by the Re-
search Ethics Board of St Joseph’s Healthcare Hamilton and
all patients gave written, informed consent. Primary lung fi-
broblasts were cultured as previously described [39] and
only tissue from cancer-free regions was used for the deriv-
ation of fibroblasts. Prior to experimentation, fibroblasts
were characterized based on morphology and vimentin
expression as well as the absence of cytokeratin (epithelial
cell marker), desmin (muscle cell marker) and α-smooth
muscle actin (α-SMA; myofibroblast marker) [39] (Figure 1).
Following characterization, cells were expanded and either
frozen in liquid nitrogen or maintained in culture as a
monolayer. For experimentation, primary fibroblasts were
cultured in MEM (Life Technologies, Gaithersburg, MD)
supplemented with 10% fetal bovine serum (FBS; HyClone
Laboratories, Logan, UT) and incubated in humidified 5%
CO2/95% air at 37°C. All fibroblast strains were used at the
earliest possible passage. For assessment of basal expression
levels, all available fibroblast strains were cultured and ana-
lyzed at the same time and were within 1 passage (passage
3–4). Additional experiments were conducted with fibro-
blasts from a minimum of three different individuals of
each patient category.
Canadian chronic obstructive lung disease (CanCOLD)
CanCOLD is a prospective longitudinal cohort study
tracking 1800 subjects and comprises 2 COPD subsets
(GOLD ≥2 and GOLD 1) and 2 subsets of non-COPD
peers, i.e., normal post bronchodilator spirometry (ever
smoker for those at-risk and never-smoker for the healthy
controls), matched for sex and age. The CanCOLD cohortTable 1 Patient characteristics of fibroblast strains
derived from lung resection
Normal At Risk COPD
n of subjects 6 15 12
Age (yr) 66.7 ± 2.6 64 ± 0.7 68.3 ± 0.9
Gender (M/F) (2/4) (8/7) (8/4)
Smoking# 0.0 36.5 ± 1.2 37.6 ± 1.3
FEV1 (%) 88.2 ± 3.3 88.2 ± 0.9 65.8 ± 2.16
FVC (%) 83 ± 3.4 92 ± 0.9 81.4 ± 2.3
FEV1/FVC (%) 88 ± 2.7 76.6 ± 0.5 55.0 ± 1.7***
Results presented as average ± SEM.
#Denotes pack-years.
***FEV1/FVC of COPD patients was significantly lower (p < 0.05) compared to
either the non-smokers or the smokers without COPD, which did not differ
from each other.is described in detail in [38]. The CanCOLD study was ap-
proved by the REB at the McGill University Health Centre
(MUHC) - Study # 09-025-BMC. Peripheral blood was
collected using PAXgene blood RNA tubes (PreAnalytiX
GmbH, Hombrechtikon, Germany) at initial visit and fro-
zen at −80°C until analysis. Clinical characteristics of the
subjects utilized in this part of the study are in Table 2.
Preparation of cigarette smoke extract (CSE)
Research grade cigarettes (3R4F) with a filter were obtained
from the Kentucky Tobacco Research Council (Lexington,
KT) and CSE generated as previously described [29,40-42].
Briefly, CSE was prepared by bubbling smoke from two cig-
arettes into 20 ml of serum-free MEM, the pH adjusted to
7.4, sterile- filtered with a 0.45-μm filter (25-mm Acrodisc;
Pall Corp., Ann Arbor, MI) and was used within 30 minutes
of preparation. An optical density of 0.65 (320 nm) was
considered to represent 100% CSE and was diluted in
serum-free MEM to 2% CSE, a concentration which po-
tently increases COX-2 expression in primary lung fibro-
blasts deficient in RelB expression [31]. For comparison of
the cigarette smoke response between the three patient
groups, experiments were conducted with fibroblasts cul-
tured at the same time utilizing the same CSE preparation
to minimize experimental variability.
Analysis of gene expression
Total RNA was isolated from media- or CSE-treated fi-
broblasts using a Qiagen miRNeasy kit (Qiagen Inc.,
Valencia, CA). For processing the CanCOLD samples,
total RNA was isolated using PAXgene blood RNA kit
(PreAnalytiX GmbH) according to the supplier’s proto-
col. In each case, RNA was eluted in 30 μl RNase-free
water and RNA content and purity was measured using
a Nanodrop 1000 spectrophotometer (Thermo Fisher
Scientific, Wilmington, DE). Reverse transcription of
total RNA was carried out in a 20-μl reaction mixture
by iScript IITM Reverse Transcription Supermix (Bio-
Rad Laboratories, Mississauga, Ontario) at 25°C for
5 min, at 42°C for 30 min and at 85°C for 5 min. Real
time (qPCR) was performed with 1 μl cDNA and
0.5 μM primers added in SsofastTM Eva Green® Super-
mix (Bio-Rad) and PCR amplification was performed
using a CFX96 Real-Time PCR Detection System (Bio-
Rad). Primer sequences for human Cox-2 are TCA-
CAGGCTTCCATTGACCAG (f ) and CCGAGGCTTT
TCTACCAGA (r) and for human RelB are TGTGGTG
AGGATCTGCTTCCAG (f ) and GGCCCGCTTTCCT
TGTTAATTC (r). Thermal cycling was initiated at
95°C for 30 sec and followed by 40 cycles of denatur-
ation at 95°C for 30 s and annealing for 5 s. Melt curves
were obtained to ensure that nonspecific products were
absent. The fluorescence detection threshold was set
above the non-template control background within the
Figure 1 Characterization of human lung fibroblasts. Representative immunofluorescence images of human lung fibroblasts derived from Normal
(non-smoker), At Risk (Smoker without COPD) and COPD subjects. Target proteins were visualized with fluorescein (green) in combination with
Hoechst (blue) nuclear stain; only the merge images are shown. C2C12 (myoblasts) and A549 (epithelial) cells were used as positive controls for
desmin and keratin. Fibroblasts from each patient type were incubated with antibodies specific to vimentin (left), desmin (middle), and keratin
(right). All human lung fibroblast derived by this method were positive for vimentin but negative for desmin and keratin and exhibited typical
fibroblast morphology. Magnification = 20x. Representative images are shown.
Table 2 Clinical characteristics of the CanCOLD Subjects
Variable Normal At Risk GOLD 1 GOLD 2+ Overall P-values
Age, in year [mean(sd)] 67.75 (5.84) 66.06 (8.44) 66.94 (11.20) 67.67 (10.22) 0.952
Sex, male gender [n(%)] 4 (25.00) 5 (31.25) 9 (56.25) 9 (50.00) 0.215
Tobacco smoking status [n(%)]
Never 16 (100.00) - 7 (43.75) 4 (22.22) <0.001*
Ex-smokers - 14 (87.50) 6 (37.50) 9 (50.00) <0.001*
Current smokers - 2 (12.50) 3 (18.75) 5 (27.78) 0.149
Cigarette smoker pack-years [mean(sd)] - 14.56 (11.26) 20.02 (26.57) 27.28 (28.78) <0.001*
Post-bronchodilator spirometry [mean(sd)]
FEV1, L 2.38 (0.48) 2.55 (0.63) 2.59 (0.56) 1.60 (0.70) <0.001*
FEV1, % predicted 101.28 (11.33) 100.04 (10.75) 101.06 (20.55) 60.62 (16.68) <0.001*
FEV1/FVC, % 76.39 (4.21) 78.23 (4.48) 67.04 (7.14) 53.18 (12.93) <0.001*
Biomarker expression [mean(sd)]
RelB (X10−3) 0.74 (1.08) 0.61 (0.19) 0.61 (0.28) 0.56 (0.16) 0.326
COX-2 (X10−3) 7.74 (8.35) 5.62 (1.94) 6.30 (2.74) 6.76 (2.95) 0.453
146a (X10-3) 0.09 (0.11) 0.46 (1.10) 0.47 (0.62) 1.22 (3.37) 0.064
*indicates significance between the groups for the clinical characteristics in each row.
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threshold (Ct) of each reaction was detected. Gene ex-
pression data were analyzed using the ΔΔCt method
normalized to housekeeping (β-actin).
Analysis of miR-146a expression
miRNA expression was assessed by two-step TaqMan®
RT-PCR (Applied Biosystems, Carlsbad, CA) for miR-
146a and U6 snRNA, a small nuclear RNA (snRNA)
used as an internal control for miRNA analysis [43,44].
miRNA expression was normalized to the U6 snRNA
levels and fold-change was determined using 2−ΔΔCt
method as we have described [31,45].
Western blot
Fibroblasts were grown to approximately 90% conflu-
ence before being treated with CSE. In separate experi-
ments, Normal fibroblasts were pretreated with the
proteasome inhibitor MG-132 (10 μM) for 2 hours prior
to addition of 2% CSE. Total cellular protein was pre-
pared using 1% IGEPAL lysis buffer [40] and 5–10 μg of
protein were fractionated on SDS-PAGE gels and
electro-blotted onto Immun-blot PVDF membrane (Bio-
Rad Laboratories, Hercules, CA). Antibodies against
RelB (1:1000; Cell Signaling), COX-2 (1:1000) (Cayman
Chemical, Ann Arbor, MI), p65 (1:1000, Santa Cruz) and
total Actin (1:50,000; Milipore, Temecula, CA) were
used to assess changes in relative expression. Proteins
were visualized using HRP-conjugated secondary anti-
bodies (1:10,000) followed by enhanced chemilumines-
cence (ECL) and imaged using a ChemiDoc™ XRS+
System (Bio-Rad).
RelB knock-down in primary lung fibroblasts
Normal fibroblasts (non-smoker) were seeded at 1–2 x
104 cells/cm2 and transfected with 40 nM of siRNA
against RelB (Santa Cruz, Catalogue number sc-36402)
or non-targeting control siRNA (Santa Cruz, Catalogue
number sc-37007) according to manufacturer’s instruc-
tions. Six hours after the transfection, the cells were
switched to serum-free MEM. On the next day, cells
were treated with 2% CSE for 3–24 hours and RNA or
protein collected for further analysis as described above.
Verification of RelB knock-down was done by western
blot.
Immunocytochemistry
Lung fibroblasts from Normal, At Risk and COPD subjects
were cultured on glass chamber slides and left untreated or
were treated with 2% CSE. Following treatments, cells were
washed once with PBS/Tween, permeabilized/fixed using
3% H2O2/methanol for 10 min, and blocked with Universal
Blocking Solution for 1 hour at room temperature. The
antibodies against RelB (1:300) and p65 (1:200) were dilutedin Antibody Diluent Solution (Dako) and incubated over-
night at 4°C. Alexa Fluor-555 anti-goat or anti-rabbit IgG
antibody was used for secondary binding (1:1000) and incu-
bated for 1 hour at room temperature. Slides were then
mounted in ProLong® Gold Anti-Fade (Invitrogen), viewed
on an Olympus IX71 fluorescent microscope (Olympus,
Ontario, Canada) and photographed using a Retiga 2000R
camera with ImagePro Plus software. Fluorescent images of
nuclei are visualized by Hoechst staining (1:2000). All pro-
cedures were performed at the same time to minimize vari-
ability in fluorescence intensity.
Statistical analysis
For experimental data utilizing human lung fibroblasts,
statistical analysis was performed using GraphPad Prism
6 (v. 6.02; La Jolla, CA). A two-way analysis of variance
(ANOVA) followed by a Newmann-Keuls test was used
to assess differences between treatment groups of more
than two factors when grouped by two variables unless
otherwise indicated. A one-way analysis of variance
(ANOVA) followed by a Newman-Keuls multiple com-
parisons test was used to assess differences in baseline
values between the three subject groups. Statistical ana-
lysis of blood mRNA/miRNA levels with clinical param-
eters was analyzed on SAS version 9.3 (SAS Institute.
Inc., Cary, N.C). Descriptive data were summarized
using means and STD distributions or counts and per-
centages for the four study groups. Statistically signifi-
cant differences among the four groups were then
compared by using ANOVA analysis (or their non-
parametric equivalence-Kruskal-Wallis Test) and the
Chi-square test as appropriate. Analysis of the correl-
ation for each of the biomarker expression (Cox-2, RelB,
miR-146a) with other biomarkers as well as clinical vari-
ables was performed using Pearson’s correlation coeffi-
cient. Results are expressed as the mean ± SEM or SD.




The clinical features of the subjects from which the lung fi-
broblasts were derived are given in Table 1. The FEV1/FVC
ratio after bronchodilators was significantly lower in the
COPD patients compared to either Normal (non-smokers)
or smokers without COPD (At Risk). Non-smokers were
identified as those individuals who were never-smokers
(0 pack-years). There was no significant difference in pack-
years between the smokers with and without COPD. All
primary lung fibroblast used in this study had typical fibro-
blast morphology (flat, elongate with oval nuclei) and
expressed vimentin (Figure 1). No staining was observed
for cytokeratin or desmin indicating that the cultured fibro-
blasts did not contain cells of epithelial or muscle origin.
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Risk- and COPD-derived lung fibroblasts
Our published data show that RelB suppresses cigarette
smoke-induced COX-2 protein expression [30]. RelB is de-
graded by cigarette smoke in vitro and in vivo [29,46], rais-
ing the possibility that reduced RelB expression due to
cigarette smoke exposure contributes to heightened COX-2
expression in COPD. RelB protein at the predicted molecu-
lar weight (MW ≈ 68 kDa) [47,48] was detectable in most
of the lung fibroblasts examined; also evident was a band
with a lower MW of ≈ 55 kDa (Figure 2A, arrows) that are
consistent in size with degradation products of RelB [49].Figure 2 Reduced RelB mRNA and protein expression in human lung fibrobl
expression was detected in most lung fibroblasts examined at the predicted M
There was an apparent decrease in RelB protein levels in the majority of lung
fibroblasts from different individuals (Normal = 6; At Risk = 15; COPD = 12
RelB protein expression in lung fibroblasts derived from the lungs of At R
compared to fibroblasts from Normal subjects). There was no significant differ
expressed as the mean ± SEM and each symbol represents fibroblasts from a
predicted MW of 68 kDa. (C) RelB mRNA- Relative RelB mRNA expression was
to Normal (1.0 ± 0.18; * p < 0.0044) fibroblasts. Results are expressed as th
fibroblasts. (D) RelB localization: Immunofluorescent imaging of quiescen
and COPD lung fibroblasts was localized to the cytoplasm (red colour) w
appeared to be qualitatively less RelB (based on intensity) in the At Risk a
two independent experiments.In fibroblasts derived from both At Risk and COPD sub-
jects, there appeared to be lower levels of RelB. Densito-
metric analysis of RelB protein at the predicted size
(MW ≈ 68 kDa, analyzed in all subsequent Figures) indi-
cated that there was a significant decrease in RelB protein
expression in human lung fibroblasts from At Risk and
COPD subjects compared to Normal (Figure 2B). There
was no significant difference in RelB protein between
smokers with and without COPD. The relative expression
level of RelB mRNA was also significantly different be-
tween Normal and either At Risk- and COPD-derived fi-
broblasts (Figure 2C). RelB was predominantly localized toasts from At Risk and COPD subjects. (A) RelB western blot- RelB protein
W of 68 kDa. A faster migrating band of≈ 55 kDa was also detected.
fibroblasts from At Risk and COPD subjects. Sample numbers refer to lung
). (B) RelB protein densitometry- there was a significant decrease in
isk (0.41 ± 0.08) as well as COPD subjects (0.38 ± 0.07) (*p = 0.0022
ence in RelB levels between At Risk and COPD fibroblasts. Results are
different individual. Densitometry is based on the band detected at the
significantly lower in At Risk (0.5 ± 0.06) and COPD (0.57 ± 0.07) compared
e mean ± SEM (fold-change) of RelB levels normalized to the Normal
t lung fibroblasts revealed that the majority of RelB in Normal, at Risk
ith minimal RelB evident in the nucleus (blue colour). Note that there
nd COPD-derived lung fibroblasts. Representative images based on
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fibroblasts cultured under basal condition, which ap-
peared noticeably reduced in the At Risk and COPD
cells (Figure 2D). Collectively, these data indicate that
cigarette smoke exposure is associated with reduced
RelB expression.
Regulation of RelB expression in human lung fibroblasts
by CSE
Exposure to cigarette smoke, but not CD40L, results in loss
of RelB protein in murine lung fibroblasts [29]. RelB is de-
graded in a signal-specific manner in T cells [50], renderingFigure 3 RelB protein expression is decreased by cigarette smoke exposur
COPD subjects were exposed to 2% CSE for 3, 6, or 24 hours and RelB mRN
increased in Normal and At Risk fibroblasts exposed to 2% CSE for 24 hour
altered by CSE in COPD lung fibroblasts. Results are expressed as the mean
subjects for each group. (B) RelB protein: There was a noticeable decrease
Basal RelB protein levels were noticeably less in At Risk and COPD lung fibr
are shown of three experiments. (C) RelB protein- Densitometry: Densitome
RelB protein expression between Normal and At Risk and COPD lung fibrob
decreased in Normal lung fibroblasts at 6 hours of exposure to 2% CSE compar
(fold-change) utilizing fibroblasts derived from three individual subjects for each
with MG-132 for 2 hours prior to cotreatment with 2% CSE for 6 hours an
following exposure to 2% CSE for 6 hours. MG-132 increased basal leve
Western blot image is representative of 3 separate experiments.it possible that chronic exposure to smoke contributes to
the loss in RelB in At Risk and COPD lung fibroblasts. To
evaluate this, we exposed lung fibroblasts to CSE via our
in vitro model of smoke exposure [29,40,51]. In lung fibro-
blasts from both Normal and At Risk subjects, there was a
significant increase in RelB mRNA following 24 hours of
exposure to 2% CSE in vitro (Figure 3A, white and grey
bars, respectively). In COPD lung fibroblasts, RelB mRNA
levels remained unchanged throughout the 24-hour ex-
posure time (Figure 3A, black bars). Consistent with
the data presented in Figure 2, basal RelB protein ex-
pression remained significantly lower in At Risk ande in Normal lung fibroblasts. Lung fibroblasts from Normal, At Risk and
A and protein levels evaluated. (A) RelB mRNA-CSE: RelB mRNA was
s (*p < 0.05 and **p < 0.001). RelB mRNA levels were not significantly
± SEM (fold-change) utilizing fibroblasts derived from 4–6 individual
in RelB protein in Normal fibroblasts exposed to 2% CSE for 6 hours.
oblasts compared to Normal fibroblasts. Representative western blots
tric analysis of RelB expression revealed a significant difference in basal
lasts in the absence of 2% CSE (media only). RelB protein expression
ed to media control (* p < 0.05). Results are expressed as the mean ± SEM
group. (D) RelB protein: MG-132: Normal lung fibroblasts were pretreated
d protein harvested for RelB expression. RelB levels were decreased
ls of RelB and prevented the loss of RelB after exposure to 2% CSE.
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ation of the in vitro experiments (Figure 3B and C).
RelB protein decreased in CSE-exposed Normal fibro-
blasts at 6 hours compared to media-only exposed cells
(Figure 3B and C). There was no further change in RelB
protein with 2% CSE exposure in fibroblasts from At
Risk or COPD subjects. The reduction in RelB protein
levels in Normal lung fibroblasts exposed to CSE was
due to degradation by the proteasome. Treatment of fi-
broblasts with the cell-permeable and reversible prote-
asome inhibitor MG-132 [52,53] increased basal RelB
protein and also attenuated the reduction in RelB pro-
tein upon exposure to 2% CSE (Figure 3D). These data
support that exposure to cigarette smoke reduces the
expression of RelB in lung fibroblasts via the prote-
asome degradation pathway.
RelB attenuates cigarette smoke-induced COX-2 expres-
sion in primary lung fibroblasts
Our published data utilizing RelB-deficient murine fi-
broblasts show that RelB potently suppresses cigarette
smoke-induced COX-2 expression [31], leading us to
speculate that lower RelB expression contribute to in-
creased COX-2 in response to CSE. In response to 2%
CSE, there was a transient increase in Cox-2 mRNA in
At Risk and COPD lung fibroblasts, with inductionFigure 4 Cox-2 mRNA and protein expression is induced by 2% CSE in Sm
significant increase in Cox-2 mRNA in COPD lung fibroblasts (black bars) ex
control); there was a significantly more Cox-2 mRNA in COPD fibroblasts at
Cox-2 mRNA in At Risk fibroblasts (grey bars). Note the lack of relative Cox-2 mR
as the mean ± SEM of 4–9 fibroblasts from each subject group. (B) COX-2
Normal fibroblasts. There was noticeably more COX-2 protein in the At Ris
earlier COPD fibroblasts (by 3 hours). Representative western blot is shopeaking at 3 hours of exposure (Figure 4A). The induc-
tion in Cox-2 mRNA was significant in the COPD lung
fibroblasts at all time-points examined compared to
media-only (Figure 4A, black bars). There was minimal
induction in Cox-2 mRNA in Normal fibroblasts in re-
sponse to CSE (Figure 4A, white bars) while Cox-2
mRNA induction in Smoker fibroblasts was moderately
higher (Figure 4B, grey bars). Exposure to 2% CSE also
increased COX-2 protein expression only modestly in Nor-
mal fibroblasts but with noticeably higher induction occur-
ring in the At Risk and COPD fibroblasts (Figure 4B), both
of which also had significantly lower RelB protein levels
(Figure 2).
To now test whether RelB is a factor that suppresses
COX-2 induction upon direct smoke exposure, we used
siRNA to knock-down RelB expression in Normal fi-
broblasts which express relatively high levels of RelB
(Figure 2A). Following confirmation of successful reduction
in RelB protein (Figure 5A), we first performed qPCR for
Cox-2 mRNA after exposure to 2% CSE. In Normal
lung fibroblasts receiving Control siRNA (i.e. with RelB
expression; siCtrl) there was low induction of Cox-2
mRNA (Figure 5B, open bars). Attenuation of RelB ex-
pression via siRNA knockdown significantly increased
Cox-2 mRNA expression when cells were exposed to
2% CSE (Figure 5B, black bars). There was also aoker and COPD lung fibroblasts. (A) Cox-2 mRNA- CSE: There was a
posed to 2% CSE for 3 hours (*** p <0.05 compared to respective
6 and 24 hours of exposure. There was a trend towards increased
NA induction in Normal lung fibroblasts (white bars). Results are expressed
protein- CSE: There was a modest induction in COX-2 protein in
k and COPD fibroblasts. The induction in COX-2 protein occurred
wn of at least 3 different experiments.
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down cells in response to 2% CSE (Figure 5C) support-
ing that the attenuation of cigarette smoke-induction of
COX-2 in vitro in Normal lung fibroblasts is associated
with RelB expression.p65 is similar between Normal, At Risk and COPD-derived
lung fibroblasts
The promoter of Cox-2 contains two NF-κB binding sites
and thus plays an important role in the transcriptional
regulation of Cox-2 expression via the classic (p65/p50)
pathway [54]. It is possible therefore that the difference
in Cox-2 expression with CSE between At Risk and
COPD (but with no difference in RelB protein- Figure 2)
could be due to altered p65 expression or nuclear
localization. Total p65 protein expression in lung fibro-
blasts from the three subject groups after exposure to
2% CSE for up to 24 hours was not noticeably different
(Figure 6A). The localization of p65 in media only cells was
largely cytoplasmic in fibroblasts from Normal, At. Risk
and COPD subjects (Figure 6B). Exposure to 2% CSE for
30 minutes [29] marginally increased nuclear p65 in all
three groups with little difference between them (Figure 6B).
Therefore alterations in p65 expression or localization can-
not account for the differential regulation of Cox-2 between
At Risk and COPD lung fibroblasts.Figure 5 siRNA-mediated knock-down of RelB potentiates CSE-induced Co
siRNA: Lung fibroblasts derived from Normal subjects were transfected
by approximately 40% compared to Ctrl-transfected (siCtrl; relative-change: 0.5
experiments. (B) Cox-2 mRNA: Normal fibroblasts transfected with RelB siRNA w
by qRT-PCR. There was a significant increase in Cox-2 mRNA expression o
*p < 0.05 compared to RelB siRNA media only; $ p < 0.05 compared to Ct
SEM, n = 4–5 experiments. (C) COX-2 protein- there was a corresponding and d
CSE compared to the siCTRL cells. Representative western blot is shown of at leCigarette smoke induction of miR-146a in Normal human
lung fibroblasts is independent of RelB expression
We recently published that RelB promotes the induction of
miR-146a in response to cigarette smoke in murine lung fi-
broblasts as a mechanism through which RelB limits COX-
2 protein levels [31]. COPD lung fibroblasts have reduced
miR-146a induction in response to pro-inflammatory cyto-
kines, a finding that correlated with increased COX-2 ex-
pression [36]. These findings led us to speculate that RelB
control over smoke-induced COX-2 expression occurs via
miR-146a. While there was significantly more basal miR-
146a in COPD lung tissue compared to Normal (Figure 7A),
there was no difference in basal levels of miR-146a between
the three fibroblast groups (Figure 7B). In Normal fibro-
blasts, but not At Risk or COPD cells, there was a signifi-
cant increase in miR-146a after exposure to 2% CSE for
3 hours (Figure 8A), the peak expression time for miR-146a
in response to cigarette smoke [31]. Knock-down of RelB
had no effect on miR-146a (Figure 8B) suggesting regula-
tion of miR-146a expression by cigarette smoke is inde-
pendent of RelB in human lung fibroblasts.
Correlation between systemic RelB, Cox-2 and miR-146a
expression and clinical features of COPD in the CanCOLD
cohort
We recently published that RelB expression correlates with
clinical features of COPD exacerbations [55]. To nextx-2 mRNA and protein expression in Normal lung fibroblasts. (A) RelB
with siRNA against RelB (siRelB). RelB protein levels were decreased
9 ± 0.065). Results are expressed as the mean ± SEM, n = 4 independent
ere exposed to 2% CSE for 6 hours and Cox-2 mRNA expression evaluated
nly when RelB expression is reduced (siRelB; fold-induction 15 ± 8;
rl siRNA exposed to 2% CSE). Results are expressed as the mean ±
ramatic increase in COX-2 protein in the siRelB fibroblasts exposed to 2%
ast two independent experiments.
Figure 6 p65 expression and localization in Normal, At Risk and COPD lung fibroblasts. (A) p65 expression: There was no perceptible difference
in p65 expression between Normal, At Risk and COPD-derived lung fibroblasts exposed to 2% CSE for up to 24 hours. Representative western blot
is shown of 3 independent experiments. (B) p65 localization: There was little perceptible difference in the localization of p65 in lung fibroblasts
from the three subject groups, which appeared predominantly cytoplasmic (red colour). Exposure to 2% CSE for 30 minutes did not appreciably
alter the localization of p65. Representative images shown are based on two independent experiments.
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sion of RelB, Cox-2 and miR-146a in COPD, we utilized the
CanCOLD cohort. Of these subjects, there was no signifi-
cant difference in terms of age and gender between the 4
study groups (Table 2). RelB and Cox-2 expression were
not significantly different between the subject groups
whereas the relative expression of miR-146a approachedFigure 7 Basal miR-146a expression in human lung fibroblasts from Normal su
There was a significant increase in miR-146a in lung tissue derived from COPD s
each symbol represents a different individual (Normal, n = 10; At Risk, n = 9; COP
miR-146a expression in lung fibroblasts derived from the three patient gr
normalized to the snRNA U6 and are expressed as fold-change compared to
individual (Normal, n = 5; At Risk, n = 13; COPD = 11).statistical significance (p = 0.064) (Table 2). Neither RelB
nor Cox-2 mRNA expression correlated with the clinical
variables evaluated in this population, including lung func-
tion (Table 3). However, miR-146a significantly correlated
with FEV1% predicted (p = 0.026) and trended towards sig-
nificance for FEV1/FVC (p = 0.065) (Table 3). There was a
significant increase in systemic miR-146a in COPD Ibjects as well as smokers with and without COPD. (A) miR-146a-lung tissue:
ubjects compared to Normal. Results are expressed as mean ± SEM and
D= 9). (B) miR-146a-fibroblasts: There was no significant difference in basal
oups. Results are expressed as the mean ± SEM of miR-146a levels
Normal fibroblasts. Each symbol represents fibroblasts from a different
Figure 8 Regulation of miR-146a by CSE is independent of RelB. (A) miR-146a- CSE: 2% CSE significantly increased miR-146a expression only in
Normal lung fibroblasts at 3 hours (fold-induction: 5.44 ± 2.4; * p < 0.05). Results are expressed as the mean ± SEM of normalized miR-146a levels;
n = 4 independent experiments utilizing fibroblasts from 4 different subjects of each phenotype; post-hoc analysis was performed by Fisher’s LSD.
(B) miR-146a-CSE RelB siRNA: There was no significant difference in basal or CSE-exposed (3 hrs) miR-146a levels in siRelB cells (black bars) compared to
siCtrl cells (open bars). Results are expressed as the mean ± SEM of normalized miR-146a levels from 2–4 independent experiments.
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a significant positive correlation between RelB and Cox-2
expression (Table 3 and Figure 10). Collectively these data
highlight a differential role for systemic versus pulmonary
RelB expression in COPD and suggest the importance of
lung structural cell RelB expression in regulating inflamma-
tion caused by smoke exposure.
Discussion
COPD is an obstructive lung disease that is increasing in
prevalence worldwide, affecting an estimated 200 million
people [56]. While the etiology of COPD is strongly
linked to smoke exposure, the underlying pathogenic
mechanisms by which smoke causes chronic, aberrant
pulmonary inflammation remains poorly defined. Nu-
merous signal transduction pathways, including the clas-
sic (p65/p50) NF-κB pathway, contribute to cigarette
smoke-induced inflammation. The pro-inflammatory ac-
tivities of the classic NF-κB pathway are counterba-
lanced by another REL protein called RelB, initiallyTable 3 Pearson correlation coefficients between biomarkers
Variable 1 Variable 2 Correla
RelB expression Cox-2 expression 0.86
RelB expression 146a −0.08
RelB expression FEV1 L −0.04
RelB expression FEV1% predicted 0.05
RelB expression FEV1/FVC 0.10
Cox-2 expression 146a −0.12
Cox-2 expression FEV1 L 0.01
Cox-2 expression FEV1% predicted 0.09
Cox-2 expression FEV1/FVC 0.10
146a FEV1 L −0.20
146a FEV1% predicted −0.28
146a FEV1/FVC −0.23
**indicates significant correlation between RelB and Cox-2 expression.identified as I-Rel for Inhibitory Rel because of its ability
to reduce the transcriptional activities of NF-κB [47].
We have published that over-expression of RelB dimin-
ishes the induction of inflammatory mediators, including
COX-2 as well as consequent lung neutrophilia caused
by cigarette smoke [29,30]. These finding highlight RelB
as a potentially important anti-inflammatory REL pro-
tein that protects against the deleterious effects of
cigarette smoke, raising the possibility that low/absent
RelB levels in the lung may predispose some individuals
who smoke to aberrant inflammation and the eventual
development of COPD. To our knowledge, we are the
first to demonstrate that lung fibroblasts from At Risk
(smokers with no airflow obstruction) and COPD sub-
jects have significantly less RelB mRNA and protein ex-
pression compared to fibroblasts from individuals who
are non-smokers (Normal).
One of the more intriguing findings from our study is
that while there was a significant decrease in RelB mRNA in
lung fibroblasts from At Risk and COPD subjects (Figure 2),and clinical variables
tion coefficient 95% CI P-value
0.78 - 0.91 <0.001**
−0.32 - 0.16 0.509
−0.28 - 0.21 0.768
−0.19 - 0.29 0.671
−0.15 - 0.34 0.418
−0.36 - 0.12 0.323
−0.24 - 0.25 0.931
−0.16 - 0.33 0.475
−0.15 - 0.34 0.428
−0.42 - 0.05 0.114
−0.49 -0.04 0.026*
−0.45 - 0.01 0.065
Figure 9 Systemic expression of Cox-2, RelB and miR-146a levels in COPD. Peripheral blood was obtained from subjects recruited as part of the
CanCOLD project and total RNA, including miRNA, was isolated and the expression of Cox-2 and RelB mRNA as well as miR-146a evaluated by
qRT-PCR. A total of 16 subjects from each category were analyzed from the CanCOLD cohort; each symbol represents a different individual. (A) RelB
mRNA- there was no significant difference in the relative expression of RelB mRNA between the subject categories. (B) Cox-2 mRNA: there
was no significant difference in the relative expression of RelB mRNA between the subject categories. (C) miR-146a: there was a significant increase in
relative miR-146a expression in COPD Gold 1 compared to Normal subjects.
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mRNA levels based on smoking status or airflow limi-
tation (Table 2). This latter observation is consistent
with our recent publication in which we demonstrated
that systemic RelB expression was associated with
health outcomes during acute exacerbations in COPD
but was not associated with clinical features during
stable-state [55]. While this difference between pul-
monary and systemic RelB expression may be reflective
of the fact that the lung fibroblasts were derived from
different subjects compared to those from which sys-
temic RelB was measured, we postulate that this dispar-
ity is reflective of fundamental differences in RelBFigure 10 Correlation between systemic RelB and Cox-2 mRNA expression
from the CanCOLD cohort. There was a significant positive correlation betwexpression, activation and function between structural
and immune cells. Whereas RelB is highly expressed
and constitutively active in lymphoid cells [57], there is
minimal RelB activity in quiescent structural cells such
as endothelial cells and fibroblasts [24,58]. In response
to certain inflammatory triggers however (e.g. IL-1β, lipo-
polysaccharide [LPS], CD40L), RelB expression and/or ac-
tivity is increased which serves to dampen the expression of
inflammation-associated proteins such as chemokines and
adhesion molecules [24,29,59]. This is not the case with im-
mune cells, where RelB does not control the production of
chemokines from LPS-stimulated macrophages [59].
Moreover the anti-inflammatory abilities of RelB inin COPD. A total of 16 subjects from each category were analyzed
een systemic RelB and Cox-2 mRNA expression.
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to non-hematopoietic cells, particularly fibroblasts. Evi-
dence in support of this includes: (1) the transfer of
normal bone marrow into irradiated RelB-deficient
mice failed to alleviated the inflammatory syndrome
and (2) injection of LPS-stimulated RelB−/− fibroblasts
potently induced inflammation in vivo [59]. Thus, it
may be that lung fibroblasts with low RelB expression
due to chronic smoke exposure (rather than immune
cells) are active participants in the abnormal inflamma-
tion associated with cigarette smoke exposure, capable
of inciting and perpetuating the pulmonary inflamma-
tory response via the production of inflammatory medi-
ators such as COX-2.
Our observation that lung fibroblasts from individuals
who smoke (At Risk) and those with airflow limitation
(COPD) have reduced RelB mRNA and protein expression
(Figure 2) suggests that cigarette smoke directly reduces
RelB levels, a notion further supported by our in vitro ex-
perimental data showing CSE exposure decreases RelB pro-
tein (Figure 3). Our data also support that the mechanism
by which smoke decreases RelB protein is due to degrad-
ation by the 26S proteasome (Figure 3D). Consistent with
this notion, others have demonstrated that RelB is proteo-
lytically degraded in T cells in a ligand-specific manner
[50,60], including the appearance of the lower MW band
of ≈ 55 kDa (Figure 2A) [49] and that RelB degradation also
occurs in pulmonary cells exposed to hypercapnia [25]. An-
other unresolved question is why there was a significant de-
crease in RelB mRNA in smoker-derived (At Risk) lung
fibroblasts (Figure 2) whereas exposure to CSE in vitro did
not significantly decrease RelB mRNA levels in any of the
subject groups (Figure 3). It is possible that chronic long-
term exposure to cigarette smoke, characteristic of individ-
uals in the At Risk and COPD categories, is necessary to
alter RelB mRNA expression, such that a single exposure to
cigarette smoke over a 24 hour time-period, our standard
in vitro exposure protocol, is insufficient to alter RelB at
the mRNA level.
It is somewhat paradoxical that there was a significant
cigarette smoke-induction of Cox-2 mRNA only in COPD
cells (and not At Risk), despite the fact that both have simi-
lar low RelB expression levels (Figures 2 and 4). At first
glance this might indicate that RelB ultimately does not
contribute to the regulation of smoke-induced COX-2.
However our data utilizing siRNA to knock-down RelB in
Normal cells, where there is potentiation of CSE-induced
Cox-2 mRNA expression (Figure 5), expands data obtained
from our in vitro and in vivo models of smoke exposure
[30] to show that RelB contributes to the suppression of
cigarette smoke-induced COX-2 in human lung cells. One
explanation for these data is that RelB is in fact critical in
attenuating COX-2 in naive cells that initially encounter re-
spiratory toxicants such as cigarette smoke, but that RelBalone is insufficient in counter-balancing the deleteri-
ous effects associated with chronic, long-term smoke
exposure in COPD subjects. It may also be that post-
translational modifications of RelB protein occur in
COPD, accounting for the differential response be-
tween At Risk and COPD-derived cells, both of which
have reduced RelB protein levels but divergent tran-
scriptional changes in Cox-2 mRNA. Protein ubiquiti-
nation, which is implicated in COPD pathogenesis [61],
augments the transactivation potential of RelB to pro-
mote NF-κB-dependent transcription [62]. Thus if such
modifications account for the difference in response
between At Risk and COPD cells, then alteration of
RelB levels (via siRNA) in At Risk fibroblasts would be
ineffectual in altering smoke-induced Cox-2 expression.
There is also no difference in the expression or nuclear
localization of p65 between the three groups in re-
sponse to CSE (Figure 6), making it unlikely that RelB
suppression of Cox-2 is via alteration in the canonical
NF-κB pathway. It remains possible that co-activators
such as p300, necessary for transcriptional induction of
Cox-2 by NF-κB [63], are repressed by RelB or altered
in COPD, thereby accounting for differences in Cox-2
between At Risk and COPD fibroblasts or the initiation
of Cox-2 transcription after RelB knock-down. More-
over, cigarette smoke exposure can cause epigenetic
changes in the lung, leading to significant increases in
inflammatory proteins associated with COPD patho-
genesis [64,65]. Thus it could also be that, in addition
to low RelB levels in COPD, there are further epigen-
etic changes in the lung or additional protein modifica-
tions to the RelB protein not identified in this study
that render it unable to exert negative control over re-
peated/chronic exposures. Such epigenetic alterations
could also be why there is reduced RelB mRNA in lung
fibroblasts from chronic smokers but not after a single
24-hour exposure. Finally, another potential explan-
ation is that a protein partner of the RelB pathway es-
sential for its full inhibitory activities (e.g. p100/p52 or
the aryl hydrocarbon receptor [AhR]) [29] may also be
inherently absent or defective in COPD subjects, and
thus not allow for the full anti-inflammatory abilities of
RelB. These and other possibilities are currently being
explored.
Recently, a reciprocal relationship between RelB and
miR-146a in immunity and inflammation has emerged in-
cluding the induction of miR-146a by IL-1β [66] and CSE
[31]. McMillan and colleagues demonstrated that in adult
lung fibroblasts, downregulation of RelB via siRNA de-
creases the magnitude of IL-1β-induced miR-146a expres-
sion [66]. Sato et al. demonstrated that COPD fibroblasts
produce less cytokine-stimulated miR-146a compared to fi-
broblasts from smokers (At Risk) [36]. In our study, both
At Risk and COPD fibroblasts also failed to significantly
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was independent of RelB expression (Figure 8), suggest-
ing that RelB does not contribute to CSE-induction of
miR-146a in human lung fibroblasts. This differs from
our recently published data utilizing RelB−/− mouse
lung fibroblasts, which has significantly less miR-146a
compared to RelB-expressing cells [31]. While this may
reflect species-specific differences in basal miR-146a
regulation, it is equally likely that even low detectable
levels of RelB expression in At Risk and COPD fibro-
blasts are sufficient to promote basal miR-146a expres-
sion. Of the potential systemic markers examined in
this study, only miR-146a was associated with health
outcomes (Table 3) and increased in COPD (Figures 7
and 9). Our findings that basal miR-146a was higher in
both COPD lung tissue as well as systemically in the
blood, but not in lung fibroblasts, suggests that cells of
hematopoietic origin- and not lung structural cells-
contribute to this heightened expression. It is also intri-
guing that miR-146a was significantly increased in COPD
Gold 1 but not with more severe disease (Gold 2+).
Whether the increased miR-146a in COPD 1 is a compen-
satory mechanism or predictive of those individuals who
will go on to develop more severe COPD is not known.
Further longitudinal assessment of miR-146a utilizing the
CanCOLD population may reveal the novelty of miR-146a
as a biomarker of COPD progression.
We recognize that there are several limitations with our
study, including the cross-sectional nature of the data ob-
tained from the fibroblasts derived from the lung surgical
specimens. This ultimately makes us unable to determine if
the individuals who are smokers with low RelB will ultim-
ately develop COPD. We also cannot exclude the possibility
that medications (e.g. inhaled corticosteroids) taken by the
subjects in our study had an impact on the relative expres-
sion levels of RelB, as corticosteroids can dampen Cox-2
gene transcription via NF-κB [67]. Finally, another per-
ceived limitation is the reliance on mRNA levels to correl-
ate with clinical parameters, as quantification of blood RelB
protein expression remains to be determined. Despite these
limitations, our data support that RelB suppresses COX-2
expression upon exposure to cigarette smoke. When con-
sidered with our previous work [31], our data implies that
RelB and miR-146a may work cooperatively to suppress
COX-2 expression in response to environmental toxicants.
Conclusions
To the best of our knowledge, we are the first to report
on the expression of RelB in primary lung fibroblasts de-
rived from COPD, and show that cigarette smoke con-
tributes to a reduction in RelB expression in lung
structural cells. Our data further demonstrate the im-
portance of RelB expression in attenuating COX-2 pro-
tein in response to in vitro exposure to cigarette smokeextract. Whether low RelB levels predispose to the de-
velopment of COPD in susceptible individuals is not
known but further molecular investigation into the alter-
native NF-κB pathway will enhance our understanding
of RelB in COPD and may contribute to the develop-
ment of novel, lung-targeted anti-inflammatory treat-
ments for smoke-related lung disorders.
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